Recently, several investors on the interactive platform successively asked Andon Health Co.Ltd(002432) for confirmation. At the Zheshang Securities Co.Ltd(601878) teleconference, an expert reported that the products of Jiu’An were unqualified and the certification might be revoked.
Subsequently, Andon Health Co.Ltd(002432) responded that the company has no such situation at present, and the rumor has no factual basis.
Regarding the statement that the experts who made Andon Health Co.Ltd(002432) related remarks on the teleconference came from Hangzhou Biotest Biotech Co.Ltd(688767) that Hangzhou Biotest Biotech Co.Ltd(688767) responded that no personnel of the company participated in the teleconference of a securities firm.
In response to the reporter of the securities times, the Zheshang Securities Co.Ltd(601878) Research Institute, the serial person of the teleconference, said that after verification, the information or opinions expressed by relevant experts in the teleconference belong to their personal views and do not represent the research views of Zheshang Securities Co.Ltd(601878) Research Institute.
On March 1, Andon Health Co.Ltd(002432) share price fluctuated and fell to the limit during the session. As of the closing, the company’s share price fell by 9.48% to close at 58.18 yuan / share. According to statistics, since reaching 88.88 yuan on January 18, Andon Health Co.Ltd(002432) share price has fallen by nearly 30%.
Three Party response to market rumors
Today, an investor asked a question on the interactive platform: a securities firm said in its teleconference that “Jiu’An’s ihealth test kit has low detection sensitivity, inaccurate test results and low reliability, and has a very poor reputation in the US market. The US FDA is ready to cancel the EUA authorization for ihealth”! In this regard, please reply positively: has the US government, FDA or other relevant subjects questioned the detection sensitivity or quality of ihealth antigen detection kit, and whether there are facts that may lead the us to raise the above questions?
In response, Andon Health Co.Ltd(002432) responded that the company has no such situation at present, and the rumor has no factual basis. If the rumor misleads and adversely affects the listed company and the capital market, the company will investigate its responsibility through legal means.
It was mentioned that the experts who made Andon Health Co.Ltd(002432) related remarks on the teleconference of a securities firm were Hangzhou Biotest Biotech Co.Ltd(688767) , Hangzhou Biotest Biotech Co.Ltd(688767) responded this afternoon that after the company’s self-examination, no personnel of the company participated in the teleconference of a securities firm. The rumor had no factual basis and was untrue. Please do not believe rumors. For malicious acts that spread rumors and damage the interests of investors, the company will reserve the right to investigate the legal responsibilities of relevant personnel through legal channels and safeguard the legitimate rights and interests of the company.
In addition, Hangzhou Biotest Biotech Co.Ltd(688767) responded to the media that the company had communicated with Zheshang Securities Co.Ltd(601878) and Zheshang Securities Co.Ltd(601878) is currently verifying the identity of the participants.
The intermediary of the conference call, Zheshang Securities Co.Ltd(601878) Research Institute responded to the reporter of the securities times, saying that after verification, the information or opinions expressed by relevant experts in the conference call belong to their personal views and do not represent the research views of Zheshang Securities Co.Ltd(601878) Research Institute.
It is understood that on February 27, 2022, Zheshang Securities Co.Ltd(601878) Institute organized an expert exchange teleconference with the theme of “covid-19 antigen detection industry analysis”. The teleconference invited experts with relevant industry background and was only open to customers of its contracting institutions.
longhubang regulars
buying one seat and selling one seat are the same business department
On March 1, Andon Health Co.Ltd(002432) trading was close to the limit, and it was on the list of dragons and tigers again after trading. According to the data, Citic Securities Company Limited(600030) Xi’an Zhuque Street securities business department is located in buy a seat, with a total purchase of 998527 million yuan. Interestingly, the sales department also sold one seat, with a total sales of 1555216 million yuan and a net sales of 556689 million yuan. Buy two to buy four seats are occupied by Dongcai Lhasa business department, namely the first securities business department of Lhasa East Ring Road, the first securities business department of Lhasa Tuanjie road and the second securities business department of Lhasa east ring road. In addition, institutional seats bought 597571 million yuan today, sold 456047 million yuan, and net bought 141524 million yuan.
In fact, since the end of last year, Andon Health Co.Ltd(002432) has become a regular guest of the dragon and tiger list. According to statistics, 17 trading days have been listed this year.
ten times bigger Bull Stock Performance soared
single quarter net profit exceeds the sum of the past 12 years
Andon Health Co.Ltd(002432) can be described as ten times the hot bull stocks in the recent market, and the company’s share price has reached the 29 limit in more than two months. The company’s share price started from the lowest price of 5.8 yuan on October 28 last year to the highest price of 88.88 yuan on January 18 this year. The cumulative increase in two and a half months exceeded 11 times, far outperforming the increase of the market and the sector. During this period, the turnover was 103.5 billion yuan, and the turnover rate was as high as 681%.
Behind the rise in share prices is the explosive growth of the company’s performance. On January 19, Andon Health Co.Ltd(002432) disclosed that the performance forecast for 2021 showed that the attributable net profit of the company is expected to reach RMB 900 million to RMB 1.2 billion in 2021, with a year-on-year increase of 271.4% – 395.19%, and the deduction of non net profit is also RMB 850 million-1.15 billion, a significant increase of 243% – 365%.
For the reasons for the growth of performance, the company said that 2021 continued to be affected by the global COVID-19 epidemic. The sales performance of New Coronavirus (SARS-CoV-2) antigen self testing OTC kit product in the US market has increased significantly, prompting the 2021 year business performance to grow substantially.
According to the third quarterly report of last year, Andon Health Co.Ltd(002432) 2021’s net profit attributable to the parent company in the first three quarters was 50.128 million yuan. Based on this calculation, the company’s net profit in the fourth quarter of 2021 is expected to reach 849 million yuan – 1.149 billion yuan, achieving the best single quarter profit. According to statistics, Andon Health Co.Ltd(002432) listed for 12 years, the company has achieved a total net profit attributable to the parent company of 118 million yuan. The company’s profit in the fourth quarter of last year exceeded seven times the total of 12 years.
Andon Health Co.Ltd(002432) announced on February 7 this year that the production and operation of the company has been normal recently, and there has been no significant change in the internal and external business environment. The US subsidiary signed a change contract with ACC on the original purchase contract. On the basis of the purchase of 250 million ihealth kit products in the original contract, 104 million ihealth kit products were purchased, and the total contract amount increased from US $1.275 billion to US $1.775 billion (about RMB 11.226 billion).
Company Risk Reminder
the U.S. government has the right to terminate the contract at any time due to its own factors
The company had previously warned that there might be a risk that the contract could not be performed on schedule or in full due to the impact of local epidemic changes, policy changes, changes in the company’s supply chain capacity, logistics and transportation risks, the right of the U.S. government to terminate the contract at any time due to its own factors, as well as unforeseen or force majeure.
The company said that due to the epidemic in the United States, the current shortage of transport capacity in air and sea channels continues, the port is congested and the backlog of goods is serious. If the shipped goods cannot be picked up in time, they will not be delivered on time according to the contract requirements. If the delivery date is seriously affected, the company may breach the contract, or the buyer may cancel the subsequent contract procurement after terminating the contract, If the contract cannot be fully implemented, the company shall also bear relevant losses.
In addition, the company also specially reminded that the U.S. government has the right to terminate the contract at any time due to its own factors. The above meaning means that the U.S. government can request to stop the execution of the contract without any reason and cancel the subsequent procurement. The Seller shall bear the corresponding risks and possible losses.
Andon Health Co.Ltd(002432) previously issued several announcements on abnormal fluctuations in stock trading, indicating that the relevant technical indicators in the company’s secondary market are relatively high compared with the company’s historical stock price and P / E ratio, and the risk of falling of the company’s future stock price and the above indicators cannot be ruled out.
